Difference between revisions of "Baker Pharmaceuticals"
Sarna News
| Line 16: | Line 16: | ||
'''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-142/> | '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-142/> | ||
| − | '''President/CEO:''' John Sleeth (circa 3024).<ref name=HSTLC-142/> | + | '''President/CEO:''' [[John Sleeth]] (circa 3024).<ref name=HSTLC-142/> |
==Overview== | ==Overview== | ||
Latest revision as of 08:23, 25 November 2023
Baker Pharmaceuticals | |
|---|---|
| Corporation Profile | |
| Headquarters | New Benner (Baker 3)[1] |
| Leadership | CEO |
Baker Pharmaceuticals was a pharmaceutical company in the Lyran Commonwealth, with its assets eventually acquired by the mammoth Nashan Diversified. [1] [2]
Company Profile[edit]
Commonwealth Stock Exchange Symbol: BakPhar. [1]
President/CEO: John Sleeth (circa 3024).[1]
Overview[edit]
Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-S-Bill lawsuit in 3023 when a batch of their synthetic molecular antibodies went toxic, killing over 100 Lyran Commonwealth Armed Forces soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in 3024, which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.[1]
While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond 3025.[1] Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer Donegal offices to serve as its Nashan Pharmaceuticals division.[2]